Embed Size (px)
Citation preview
Measles Initiative Management and FinancingSeptember 13, 2011
OverviewOverview
MI management and finance mechanism – strengths and challenges
Financial update
MI ProcessMI Process
0
Monitoring and evaluation
Reporting
Review, consolidate and prioritize
Fundraising
0
Implementation
Annual country plans
Disbursement
Management
Management - StrengthsManagement - Strengths Country driven
No secretariat
Flexible
Transparent
Defined roles and responsibilities: with shared responsibility and credit
Well coordinated: avoids programme fragmentation
Clearly defined monitoring and evaluation indicators and process
Accountable: accurate & detailed reporting of results & resources on annual basis
ManagementManagement
Balance needs of each partner agency with needs of the MI
MI communication/advocacy support hired
MI branded communication tools
– MI.org, Facebook, Twitter, Storify, etc.
Challenge Tactic
ManagementManagement
Raise awareness of partnership and goals
Advocacy survey– Inform direction of MI advocacy
team
MI advocacy team (MIAT)– Finalizing TORs, structure and
management, short-term workplan
Challenge Tactic
“The Measles Fund”
Financial MechanismARC CDC
UNF (matching funds)
UNFIP
WHO/HQ UNICEF/NY UNICEF/Supply
WHO/Country UNICEF/Country
MOH, Red Cross/Crescent Societies, Lions, LDS and other NGOsICC
(Donor Partners)
(UN Partners)
(In-Country Partners)
OperationalCosts, Technical Assistance, and
Lab/Surveillance
CountryPlans
Vaccine/SyringesC
ount
ry P
lans
Note: Funds are released when ICC-approved country plans are approved by partners.
Other Donors
Financial Mechanism - StrengthsFinancial Mechanism - Strengths
Flexible
Rapid and full disbursement of funds
Able to balance WHO and UNICEF funding needs in different settings
Low overhead costs
Low transaction costs for donors, partners and countries (one pooled donor fund, one proposal, one report)
Streamlined: joint resource mobilization
Financial MechanismFinancial Mechanism
Decline in funds available Additional resource mobilization support
– TORS developed, interviews underway
New partners
Measles mortality reduction investment case (Dec. 2011)
Eradication investment case (Apr. 2012)
High net worth individuals investment case (near final)
Challenge Tactic
0
20
40
60
80
100
120
140
160
180
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
$ U
S M
illio
n
Donations
Measles Initiative Annual Donations, 2001-2011*
*Excluding country contributions
Financial MechanismFinancial Mechanism
Large outbreaks that require emergency ORI– $30m in 2010 and in 2011
Sufficient funds for high quality preventative campaigns
Ongoing discussions regarding outbreak response fund
Coordination with other humanitarian agencies
Challenge Tactic
Measles Case Distribution by Month, Sub-Saharan Africa 2006-2010
Financial MechanismFinancial Mechanism
Non-binding agreement with countries to finance 50% of SIA costs
On-going discussions with GAVI and other partners to explore common standards for implementing country co-financing
MI advocacy team to focus on raising political and financial commitment from implementing countries
Challenge Tactic
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
Am
ou
nt
of
mo
ney r
ais
ed
lo
ca
lly (
US
D p
er
ch
ild
targ
ete
d)
~ 50% of ops costs (USD 0.32 per child)
Financial UpdateFinancial Update
Historic Measles Initiative SupportHistoric Measles Initiative Support
Technical– Vaccination and surveillance strategies– Program planning, implementation, M and E
Financial– Bundled vaccine– SIA operational costs
• 100% catch-up campaigns
• 50% for follow-up campaigns
– Lab and surveillance– Technical assistance
Advocacy and communication
Additional Cost Elements to Achieve GoalsAdditional Cost Elements to Achieve Goals
Research
Outbreak response
Routine– Scale up of MCV1– MCV2 introduction
Rubella – Catch-up campaigns– Introduction into routine
0
20
40
60
80
100
120
140
160
180
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
$ U
S M
illio
n
Donations Projected Donations Funding Gap
Funding Gap 2012: $43.4 million
Annual Donations 2001-2011 and Financial Resource Requirements, Projections, Funding Gap 2012
* Excluding country contributions
CDC
ARC*
IFFIm UNICEF
CIDA
UNF**
GAVI
NorwayBMGF
LDSJapan
Merck
Total: $987 million (excluding country contributions for follow-up SIAs, & intro. of MCV2)
*includes ARC and partners: ARC chapter contributions, Anne Ray Charitable Trust, BD, Herman and Katherine Peters Foundation, and others
** includes UNF and partners
External Contributions, Projected Contributions and Funding Gap for 2001-2012
2012 funding gap US$43.4 m
Next StepsNext Steps
Financial resource requirements, 2011-2015
Measles eradication investment case– global burden of disease – expected benefits, risks, and costs of the eradication and
comparator options (i.e., control)– social, political, and economic challenges – ethical considerations– operational and other research needs – different financial instruments and funding mechanisms – options for management and governance
